Eli Lilly and Company (LLY) News Today

Eli Lilly and Company (NYSE:LLY) shares have edged higher today on a string of clinical updates, analyst ratings and sector news that highlight both the company’s growth prospects and near-term risks. Key developments influencing investor sentiment include:

• Positive Sentiment: Mounjaro’s trial data suggest it may lower cancer risk, extending potential use beyond diabetes and obesityEli Lilly's (LLY) Mounjaro Shows Potential in Reducing Cancer Risk
• Positive Sentiment: Phase 3 study shows mirikizumab may become a new pediatric ulcerative colitis treatmentEli Lilly’s Mirikizumab Study: A Promising Step for Pediatric Ulcerative Colitis Treatment
• Positive Sentiment: Pediatric arthritis trial readout could be a game-changer for juvenile rheumatoid conditionsEli Lilly’s Pediatric Arthritis Study: A Potential Game-Changer?
• Positive Sentiment: LY3849891 trial shows promise for treating liver disease, expanding Lilly’s pipeline in metabolic disordersEli Lilly’s New Study on LY3849891: A Potential Game-Changer for Liver Disease Treatment?
• Positive Sentiment: Lebrikizumab Phase 3 data point to a potential blockbuster for atopic dermatitisEli Lilly’s Lebrikizumab Study: A Potential Game-Changer for Atopic Dermatitis
• Positive Sentiment: Early cancer therapy study shows encouraging results, supporting long-term oncology growthEli Lilly’s Promising Cancer Therapy Study: A Potential Game-Changer?
• Positive Sentiment: Guggenheim reiterates a Buy rating and raises its price target to $875Guggenheim Maintains a Buy Rating on Eli Lilly and Company (LLY), Sets a $875 PT
• Positive Sentiment: Investor interest remains strong in the weight-loss theme as Ozempic-driven momentum supports broader healthcare betsOzempic Boom: Hims & Eli Lilly Lead Healthcare Bets (LLY)
• Positive Sentiment: LLY is trading up roughly 1.5% after analysts highlight strong fundamentals and growth outlookEli Lilly and Company (NYSE:LLY) Trading Up 1.5% - Should You Buy?
• Neutral Sentiment: Lilly to present at Wells Fargo’s 20th Annual Healthcare Conference on Sept. 5, offering visibility into its pipeline strategyLilly to participate in Wells Fargo 20th Annual Healthcare Conference
• Neutral Sentiment: Zacks notes LLY as a highly searched stock, outlining key facts before placing new betsEli Lilly and Company (LLY) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: MarketBeat screeners list LLY among top pharmaceutical stocks to watch on Aug. 21Promising Pharmaceutical Stocks To Follow Now - August 21st
• Neutral Sentiment: MarketBeat screeners also highlighted LLY among leading pharma names on Aug. 20Promising Pharmaceutical Stocks To Follow Today - August 20th
• Neutral Sentiment: LLY announces the planned 2025 retirement of neuroscience leader Anne White, raising succession planning focusEli Lilly (LLY) Announces Retirement Of Influential Neuroscience Leader Anne White In 2025
• Negative Sentiment: Portnoy Law Firm launches an investigation into LLY for potential investor claims, underscoring litigation riskEli Lilly and Company Investors: Company Investigated by the Portnoy Law Firm
• Negative Sentiment: Obesity pill orforglipron shows lower-than-expected weight loss in trials, raising questions about sales potentialIs Orforglipron Pill Setback End of the Road for LLY's Obesity Plans?
• Negative Sentiment: Analysis warns LLY is on pace for its worst annual performance since 2008, highlighting near-term market headwindsEli Lilly Stock Is On Track for Its Worst Performance Since 2008. Should Investors Be Worried?
• Negative Sentiment: Shares briefly fell nearly 2% on Aug. 20 amid profit-taking and sector rotationEli Lilly and Company (NYSE:LLY) Shares Down 1.9% - What's Next?